Skip to search formSkip to main contentSkip to account menu

crisnatol

Known as: 1,3-Propanediol, 2-((6-chrysenylmethyl)amino)-2-methyl-, 2-(6-(chrysenylmethyl)amino)-2-methyl-1,3-propanediol 
National Institutes of Health

Related topics

Related topics

3 relations

Broader (2)

ChrysenesPropylene Glycols
crisnatol mesylate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1998
1998
Correlation of cytotoxicity and protein-associated DNA strand breaks for 2-(arylmethylamino)-1,3-propanediols.
A mechanism of action study was performed with 14 novel DNA binding agents characterized structurally as 2-(arylmethylamino)-1,3… 
1991
1991
Polyploidy induction as a consequence of topoisomerase inhibition. A flow cytometric assessment.
1991
1991
2-[(arylmethyl) amino]-2-methyl-1,3-propanediol DNA intercalators. An examination of the effects of aromatic ring variation on antitumor activity and DNA binding.
The effects of variation of aromatic ring size, shape, and side-chain position on antitumor activity and DNA binding in a series… 
1991
1991
Phase I evaluation of crisnatol (BWA770U mesylate) on a monthly extended infusion schedule.
Crisnatol is an arylmethylaminopropanediol derivative that has shown promise as an antitumor agent in preclinical testing. In a… 
1991
1991
Metabolism of a novel antitumor agent, crisnatol, by a human hepatoma cell line, Hep G2, and hepatic microsomes. Characterization of metabolites.
1991
1991
Effects of isomeric 2-(Arylmethylamino)-1,3-propanediols (AMAPs) and clinically established agents on macromolecular synthesis in P388 and MCF-7 cells
SummaryThe in vitro effects of the 2-(arylmethylamino)-1,3-propanediols (AMAPs) on macromolecular synthesis have been examined… 
Highly Cited
1990
Highly Cited
1990
(1-Pyrenylmethyl)amino alcohols, a new class of antitumor DNA intercalators. Discovery and initial amine side chain structure-activity studies.
In the series of 1-pyrenylmethylamines studied in this work the relationships among structure, interaction with DNA, and murine… 
1989
1989
In vitro pharmacodynamic assay for cancer drug development: application to crisnatol, a new DNA intercalator.
A microtiter pharmacodynamic assay is described that evaluates antitumor activity in vitro within a matrix of extracellular drug… 
1989
1989
Limitations of the fluorescent probe viability assay.
In vitro assessment of the efficacy/capacity of toxicants (e.g., cancer chemotherapeutic agents, environmental pollutants, etc… 
1988
1988
Phase I and clinical pharmacology trial of crisnatol (BWA770U mesylate) using a monthly single-dose schedule.
Crisnatol is a novel lipophilic arylmethylaminopropanediol with significant antineoplastic activity in a variety of murine and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)